> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Teva sNDA Approved for ArmonAir Digihaler
- URL: https://www.fdaweb.com/teva-snda-approved-for-armonair-digihaler/
- Published: 2020-02-24T12:00:00.000Z
- Updated: 2026-09-14T16:04:08.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146162

FDA has approved a Teva Respiratory supplemental NDA for ArmonAir Digihaler (fluticasone propionate) Inhalation Powder, an inhaled corticosteroid delivered by Teva’s Digihaler device for asthma maintenance treatment. The inhaler contains built-in sensors and connects to a companion mobile application that provides information on inhaler use to people with asthma, the company says.

The wireless usage data are sent to a companion mobile app using Bluetooth Wireless Technology so that patients can review their data over time or share it with their healthcare providers, the company says. Patients also can schedule dosage reminders on their smartphones.

Previously, AirDuo was indicated for treating asthma in patients 12 years of age and older.